Search results
Results from the WOW.Com Content Network
The time between hepatitis B infection and development into HCC can be years, even decades, but from diagnosis of HCC to death, the average survival period is only 5.9 months according to one Chinese study during the 1970-80s, or 3 months (median survival time) in sub-Saharan Africa according to Manson's textbook of tropical diseases. HCC is ...
The most frequent liver cancer, accounting for approximately 75% of all primary liver cancers, is hepatocellular carcinoma (HCC). [15] HCC is a cancer formed by liver cells, known as hepatocytes, that become malignant. In terms of cancer deaths, worldwide HCC is considered the 3rd most common cause of cancer mortalities. [16]
In statistics, median follow-up is the median time between a specified event and the time when data on outcomes are gathered. The concept is used in cancer survival analyses. [citation needed] Many cancer studies aim to assess the time between two events of interest, such as from treatment to remission, treatment to relapse, or diagnosis to death.
Hepatocellular adenomas (also called hepatocellular adenoma) are rare benign liver tumors made up of hepatocytes, [2] with estimates indicating hepatocellular adenomas make up 2% of liver tumors. [7] They are most common in women using contraceptives or hormone replacement therapies containing estrogen , women who are pregnant, or people mis ...
Several types of cancer are associated with high survival rates, including breast, prostate, testicular and colon cancer. Brain and pancreatic cancers have much lower median survival rates which have not improved as dramatically over the last forty years. [4] Indeed, pancreatic cancer has one of the worst survival rates of all cancers.
The European Liver Transplant Registry considers liver angiosarcoma an absolute contraindication to liver transplantation, [15] reporting that the median survival following liver transplantation is less than 7 months with no one surviving more than 23 months, showing very little difference from no treatment at all. [2] [6]
In a randomized, double-blind, phase II trial combining sorafenib with doxorubicin, the median time to progression was not significantly delayed compared with doxorubicin alone in patients with advanced hepatocellular carcinoma. Median durations of overall survival and progression-free survival were significantly longer in patients receiving ...
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...